All In Biotech

Drug Trial Radar · NCT07260877

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus

Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

Dec 3, 2025

Primary completion

Dec 2026

Study completion Mar 2027

Sponsor

Lead sponsor
Ventus Therapeutics U.S., Inc.Industry
Sponsor type
Industry
First posted
Dec 3, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if VENT-03 works to treat patients with cutaneous lupus erythematosus (CLE) who may or may not have systemic lupus erythematosus (SLE). Another goal is to learn about the safety of VENT-03 and how it is processed by the body. The main questions it aims to answer are: * Does VENT-03 affect the activity and severity of CLE? * What side effects do participants have when taking VENT-03? Researchers will compare VENT-03 to a placebo (a look-alike substance that contains no drug) to see if VENT-03 works to treat patients with CLE. Participants will: * Take VENT-03 or a placebo for 4 weeks, then all participants will switch to VENT-03 for another 8 weeks; * Visit the clinic once a month for checkups and tests.

Conditions

  • Cutaneous Lupus Erythematosus (CLE)
  • Systemic Lupus Erythematosus
  • SLE
  • SLE (Systemic Lupus)
  • CLE

Interventions

  • VENT-03Drug

    VENT-03 is a tablet

  • PlaceboDrug

    Placebo is a tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate the effect of VENT-03 on the interferon gene signature in the skinTime frame: Baseline to End of Double-Blind Treatment (up to Day 28)

Locations

34 sites in 8 countries. Site status is shown where the registry gives one.

  • Investigative Site

    Beverly Hills, California

  • Investigative Site

    Clearwater, Florida

  • Investigative Site

    DeBary, Florida

  • Investigative Site

    Miami, Florida

  • Investigative Site

    Tampa, Florida

  • Investigative Site

    Indianapolis, Indiana

  • Investigative Site

    Flint, Michigan

  • Investigative Site

    Troy, Michigan

  • Investigative Site

    Saint Joseph, Missouri

  • Investigative Site

    Albuquerque, New Mexico

  • Investigative Site

    Fairport, New York

  • Investigative Site

    Memphis, Tennessee

  • Investigative Site

    Allen, Texas

  • Investigative Site

    Arlington, Texas

  • Investigative Site

    Colleyville, Texas

  • Investigative Site

    Haskovo, Bulgaria

  • Investigative Site

    Plovdiv, Bulgaria

  • Investigative Site

    Sofia, Bulgaria

  • Investigative Site

    Paris, France

  • Investigative Site

    Toulouse, France

  • Investigative Site

    Tbilisi, Georgia

  • Investigative Site

    Szeged, Hungary

  • Investigative Site

    Bialystok, Poland

  • Investigative Site

    Oświęcim, Poland

  • Investigative Site

    Poznan, Poland

  • Investigative Site

    Rzeszów, Poland

  • Investigative Site

    Śląskie, Poland

  • Investigative Site

    Warsaw, Poland

  • Investigative Site

    Wroclaw, Poland

  • Investigative Site

    Durban, South Africa

  • Investigative Site

    Pretoria, South Africa

  • Investigative Site

    Somerset West, South Africa

  • Investigative Site

    Badajoz, Spain

  • Investigative Site

    Madrid, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.